Abstract
Abstract
Purpose
In endometrial cancer, the incidence of mutations in mismatch repair genes (MMR) is estimated at 17–30%. Patients with alterations at this level (MSI) are known to have different clinical and anatomopathological characteristics than those without this genetic alteration (MSS). In this study, we aim to identify the MSI phenotype in patients who underwent hysterectomy for endometrial cancer. We assessed the correlation of this phenotype with anatomoclinical parameters such as obesity and histological subtype.
Methods/patients
Clinical and anatomopathological data were collected from 147 patients diagnosed with endometrial cancer and an immunohistochemical study of MMR system proteins was performed. PMS2 and MSH6 proteins were evaluated as primary screening and subsequent evaluation of MLH1 and MSH6, respectively, if the former were negative. Statistical association between the anatomopathological data and the immunohistochemical result was analyzed.
Results and conclusions
22.4% of our patients were MSI phenotype. We obtained statistically significant differences by multivariate analysis between endometrioid subtype and higher FIGO classification grade with MSI phenotype and obesity with MSS phenotype. Given these statistical results, we propose a function for predicting the probability of being MSI phenotype taking into account the histological subtype (endometrioid/non-endometrioid carcinoma) and FIGO grade as well as obesity. This prediction may be useful prior to hysterectomy, for genetic study of the MLH1 promoter and subsequent genetic counseling.
Funder
Universidad de las Palmas de Gran Canaria
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference34 articles.
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019. https://doi.org/10.1002/ijc.31937.
2. Alemán Herrera A, Rojas Martín MD, Red Española de Registros de Cáncer. Estimaciones de la incidencia de cáncer. Canarias 2018. Red Española Regist Cáncer. 2019;1–20. https://www3.gobiernodecanarias.org/sanidad/scs/content/8e1d1c9c-43fd-11e9-af3a-bd8e6246c9be/Estimacion_Incidencia_Cancer_Canarias2018.pdf
3. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 1993;53(21):5100–3 (PMID: 8221644).
4. Doghri R, Houcine Y, Boujelbène N, et al. Mismatch repair deficiency in endometrial cancer: immunohistochemistry staining and clinical implications. Appl Immunohistochem Mol Morphol. 2019;27(9):678–82. https://doi.org/10.1097/PAI.0000000000000641.
5. Colle R, Cohen R, Cochereau D, Duval A, Lascols O, Lopez-Trabada D, et al. Immunotherapy and patients treated for cancer with microsatellite instability. Bull Cancer. 2017;104(1):42–51. https://doi.org/10.1016/j.bulcan.2016.11.006.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献